Researcher Profile

Researcher Profile

David Degraff, PhD

David Degraff, PhD

Assistant Professor, Department of Pathology and Laboratory Medicine
Division of Experimental Pathology
Assistant Professor, Department of Surgery
Scientific Program:Next-Generation Therapies
djd32@psu.edu

Research Interests

  • Urinary Bladder Neoplasms
  • Neoplasms
  • Prostate
  • Carcinoma
  • Prostatic Neoplasms
  • Urinary Bladder
  • Proteins
  • Transcription Factors
  • Androgens
  • Gene Expression
  • Androgen Receptors
  • Insulin-Like Growth Factor Binding Protein 2

Clinical Trials

Creation of a Clinical and Pathologic Tissue Microarray Registry for Radical Cystectomy Specimens

Recent Publications

2020

Li, H, Zhang, Q, Shuman, L, Kaag, M, Raman, JD, Merrill, S, DeGraff, DJ, Warrick, JI & Chen, G 2020, 'Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes', Scientific reports, vol. 10, no. 1, 1439. https://doi.org/10.1038/s41598-020-58351-6
Russo, M, Newell, JM, Budurlean, L, Houser, KR, Sheldon, K, Kesterson, J, Phaeton, R, Hossler, C, Rosenberg, J, DeGraff, D, Shuman, L, Broach, JR & Warrick, JI 2020, 'Mutational profile of endometrial hyperplasia and risk of progression to endometrioid adenocarcinoma', Cancer, vol. 126, no. 12, pp. 2775-2783. https://doi.org/10.1002/cncr.32822

2019

Buckwalter, JM, Chan, W, Shuman, L, Wildermuth, T, Ellis-Mohl, J, Walter, V, Warrick, JI, Wu, XR, Kaag, M, Raman, JD & Degraff, DJ 2019, 'Characterization of histone deacetylase expression within in vitro and in vivo bladder cancer model systems', International journal of molecular sciences, vol. 20, no. 10, 2599. https://doi.org/10.3390/ijms20102599
Osei-Amponsa, V, Buckwalter, JM, Shuman, L, Zheng, Z, Yamashita, H, Walter, V, Wildermuth, T, Ellis-Mohl, J, Liu, C, Warrick, JI, Shantz, LM, Feehan, RP, Al-Ahmadie, H, Mendelsohn, C, Raman, JD, Kaestner, KH, Wu, XR & DeGraff, DJ 2020, 'Hypermethylation of FOXA1 and allelic loss of PTEN drive squamous differentiation and promote heterogeneity in bladder cancer', Oncogene, vol. 39, no. 6, pp. 1302-1317. https://doi.org/10.1038/s41388-019-1063-4
Yee, CH, Zheng, Z, Shuman, L, Yamashita, H, Warrick, J, Wu, XR, Raman, J & Degraff, D 2019, 'Maintenance of the bladder cancer precursor urothelial hyperplasia requires FOXA1 and persistent expression of oncogenic HRAS', Scientific reports, vol. 9, no. 1, 270. https://doi.org/10.1038/s41598-018-36720-6
Zaleski, M, Gogoj, A, Walter, V, Raman, JD, Kaag, M, Merrill, SB, Drabick, J, Joshi, M, Holder, S, DeGraff, DJ & Warrick, JI 2019, 'Mitotic activity in noninvasive papillary urothelial carcinoma: its value in predicting tumor recurrence and comparison with the contemporary 2-tier grading system', Human Pathology, vol. 84, pp. 275-282. https://doi.org/10.1016/j.humpath.2018.10.008
Seyer, AK, Lehman, HL & Degraff, DJ 2019, 'Modeling Tumor Heterogeneity in Bladder Cancer: The Current State of the Field and Future Needs', Bladder Cancer, vol. 5, no. 4, pp. 251-261. https://doi.org/10.3233/BLC-199009
Yamashita, H, Kawasawa, YI, Shuman, L, Zheng, Z, Tran, T, Walter, V, Warrick, JI, Chen, G, Al-Ahmadie, H, Kaag, M, Wong, PK, Raman, JD & DeGraff, DJ 2019, 'Repression of transcription factor AP-2 alpha by PPARγ reveals a novel transcriptional circuit in basal-squamous bladder cancer', Oncogenesis, vol. 8, no. 12, 69. https://doi.org/10.1038/s41389-019-0178-3
Buj, R, Chen, CW, Dahl, ES, Leon, KE, Kuskovsky, R, Maglakelidze, N, Navaratnarajah, M, Zhang, G, Doan, MT, Jiang, H, Zaleski, M, Kutzler, L, Lacko, H, Lu, Y, Mills, GB, Gowda, R, Robertson, GP, Warrick, JI, Herlyn, M, Imamura, Y, Kimball, SR, DeGraff, DJ, Snyder, NW & Aird, KM 2019, 'Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming', Cell Reports, vol. 28, no. 8, pp. 1971-1980.e8. https://doi.org/10.1016/j.celrep.2019.07.084

2018

Warrick, JI, Sjödahl, G, Kaag, M, Raman, JD, Merrill, S, Shuman, L, Chen, G, Walter, V & DeGraff, DJ 2019, 'Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants [Figure presented]', European Urology, vol. 75, no. 1, pp. 18-22. https://doi.org/10.1016/j.eururo.2018.09.003

2017

Shah, TS, Kaag, MG, Raman, J, Chan, W, Tran, T, Kunchala, S, Shuman, L, Degraff, D, Chen, G & Warrick, J 2017, 'Clinical significance of prominent retraction clefts in invasive urothelial carcinoma', Human Pathology, vol. 61, pp. 90-96. https://doi.org/10.1016/j.humpath.2016.10.021
Warrick, JI, Kaag, M, Raman, JD, Chan, W, Tran, T, Kunchala, S, Shuman, L, DeGraff, D & Chen, G 2017, 'FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma', Virchows Archiv, vol. 471, no. 3, pp. 337-345. https://doi.org/10.1007/s00428-017-2190-3
Flaig, TW, Kamat, AM, Hansel, D, Ingersoll, MA, Barton Grossman, H, Mendelsohn, C, Degraff, D, Liao, JC & Taylor, JA 2017, 'Proceedings of the 3rd annual albert institute for bladder cancer research symposium', Bladder Cancer, vol. 3, no. 3, pp. 211-223. https://doi.org/10.3233/BLC-170111

2016

Raman, JD, Warrick, JI, Caruso, C, Yang, Z, Shuman, L, Bruggeman, RD, Shariat, S, Karam, JA, Wood, C, Weizer, AZ, Remzi, M, Haitel, A, Bensalah, K, Rioux-Leclerq, N, Bolenz, C, Roscigno, M, Krabbe, LM, Kapur, P, Lotan, Y, Margulis, V & DeGraff, DJ 2016, 'Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract', Urology, vol. 94, pp. 314.e1-314.e7. https://doi.org/10.1016/j.urology.2016.05.030
Warrick, JI, Raman, JD, Kaag, M, Bruggeman, T, Cates, J, Clark, P & DeGraff, DJ 2016, 'Enhancer of zeste homolog 2 (EZH2) expression in bladder cancer', Urologic Oncology: Seminars and Original Investigations, vol. 34, no. 6, pp. 258.e1-258.e6. https://doi.org/10.1016/j.urolonc.2016.02.011
Warrick, JI, Walter, V, Yamashita, H, Chung, E, Shuman, L, Amponsa, VO, Zheng, Z, Chan, W, Whitcomb, TL, Yue, F, Iyyanki, T, Kawasawa, YI, Kaag, M, Guo, W, Raman, JD, Park, JS & Degraff, DJ 2016, 'FOXA1, GATA3 and PPARIγ Cooperate to drive luminal subtype in bladder cancer: A molecular analysis of established human cell lines', Scientific reports, vol. 6, 38531. https://doi.org/10.1038/srep38531
Vasekar, M, Degraff, D & Joshi, M 2016, 'Immunotherapy in bladder cancer', Current Molecular Pharmacology, vol. 9, no. 3, pp. 242-251. https://doi.org/10.2174/1874467208666150716120945
Grabowska, MM, Kelly, SM, Reese, AL, Cates, JM, Case, TC, Zhang, J, Degraff, DJ, Strand, DW, Miller, NL, Clark, PE, Hayward, SW, Gronostajski, RM, Anderson, PD & Matusik, RJ 2016, 'NFIB regulates transcriptional networks that control the development of prostatic hyperplasia', Endocrinology, vol. 157, no. 3, pp. 1094-1109. https://doi.org/10.1210/en.2015-1312
Yamashita, H, Amponsa, VO, Warrick, JI, Zheng, Z, Clark, PE, Raman, JD, Wu, XR, Mendelsohn, C & Degraff, DJ 2017, 'On a FOX hunt: Functions of FOX transcriptional regulators in bladder cancer', Nature Reviews Urology, vol. 14, no. 2, pp. 98-106. https://doi.org/10.1038/nrurol.2016.239

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)